Tau Degradation Assay Service

Are you developing innovative therapies for Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), or other tau-related neurodegenerative disorders? Our cutting-edge CRO platform specializes in tau degradation assay analysis, providing comprehensive, multi-dimensional evaluations to accelerate your research. From in vitro models to patient-derived neurons, we offer the critical data you need to understand tau pathology and develop effective treatments. Our expertise in targeted protein degradation technology ensures accurate, reliable, and translatable results. For further information regarding the products and services provided, project-specific consultation, and pricing, please submit an inquiry here.

Introduction

The degradation of tau protein is mainly mediated by the proteasome system and the autophagy-lysosome system. The proteasome system includes the ATP/ubiquitin-dependent 20S proteasome and the non-ubiquitin-dependent 26S proteasome, which are responsible for degrading tau protein under normal circumstances. In addition, ubiquitin ligases (such as E3 ligases) also play an important role in the degradation of tau protein.

The autophagy-lysosome system clears extracellular and intracellular tau protein aggregates by phagocytosis of microglia and macrophages. For example, LC3-associated endocytosis (LANDO) has been shown to promote clearance of tau protein.

Tau Degradation Assays

• Diverse Disease Model Validation

We provide a variety of models, including: Mutation-specific models: covering tau-A152T (risk variant) and tau-P301L (dominant pathogenic mutation) neurons, demonstrating differences in the efficacy of degraders in different pathological backgrounds. Patient-derived iPSC models: simulating real disease heterogeneity, evaluating the ability of degraders to clear insoluble tau and seed activity, and providing a basis for personalized treatment.

• Multi-Dimensional Detection and In-Depth Data Analysis

Degradation efficiency and dynamic changes are accurately measured using a combination of techniques, including Western blot analysis for total tau and phosphorylated tau at S396 and other sites, ELISA for serum/cerebrospinal fluid tau fragments, and mass spectrometry. The long-term benefits of degradants on synaptic function and neuroprotection are then assessed through live cell imaging to monitor tau aggregates in real-time and cognitive behavioral models.

Case Study: QC-01-175 promotes tau clearance in a human neuronal cell model of tauopathy.

Fig.2 Tau protein levels in A152T and control neurons. Total Tau (Tau5) and phospho-Tau (S396 P-Tau) levels were analyzed by Western blotting and ELISA after treatment.^{2, 3}

Partner with us to accelerate your tau research. Our custom tau degradation assay service empowers researchers to gain deeper insights into tau protein regulation and develop more effective treatments. Contact us to discuss your specific research needs and how we can help you screen and identify novel degraders.

References

1. Miller, Lauren VC, et al. "Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function." Cell 187.21 (2024): 5967-5980.
2. Silva, M. Catarina, et al. "Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models." elife 8 (2019): e45457.
3. Distributed under Open Access license CC BY 4.0, without modification.